Get the Stockscreener App
3.247
2.64%
-0.0882
Curis Inc stock is traded at $3.247, with a volume of 10,889.
It is down -2.64% in the last 24 hours and down -12.95% over the past month.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$3.3352
Open:
$3.34
24h Volume:
10,889
Relative Volume:
0.09
Market Cap:
$28.24M
Revenue:
$10.16M
Net Income/Loss:
$-47.57M
P/E Ratio:
-0.3941
EPS:
-8.24
Net Cash Flow:
$-42.73M
1W Performance:
-7.76%
1M Performance:
-12.95%
6M Performance:
-26.37%
1Y Performance:
-65.42%
1-Day Range:
$3.2001
$3.34
1-Week Range:
$3.2001
$3.5699
52-Week Range:
$2.86
$17.49
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
3.27 | 28.24M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.53 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.11 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis (CRIS) Projected to Post Earnings on Thursday - Defense World
Cantor Fitzgerald Comments on Curis FY2025 Earnings - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Curis stock plunges to 52-week low, now at $3.0 By Investing.com - Investing.com Nigeria
Curis stock plunges to 52-week low, now at $3.0 - Investing.com
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Critical Comparison: Curis (NASDAQ:CRIS) vs. Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Curis, Inc. (NASDAQ:CRIS) Short Interest Down 39.4% in December - Defense World
Curis Inc (CRIS) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 - The Eastern Progress Online
Curis stock plunges to 52-week low, hits $3.5 amid downturn By Investing.com - Investing.com South Africa
Curis stock plunges to 52-week low, hits $3.5 amid downturn - Investing.com Canada
Curis reports promising AML study results By Investing.com - Investing.com Canada
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study - Marketscreener.com
Curis reports promising AML study results - Investing.com India
Curis Announces Additional Data from TakeAim Leukemia Study - PR Newswire
Curis (NASDAQ:CRIS) Shares Down 2.3% – Time to Sell? - Defense World
Curis (CRIS) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Curis to Present at Upcoming Healthcare Conferences in September - The Eastern Progress Online
Curis Inc (CRIS) Stock Surges 5.46% Amid Positive Analyst Ratings - GuruFocus.com
Curis Announces $12.1 Million Registered Direct and Concurrent P - GuruFocus.com
Curis to Report Third Quarter 2024 Financial and Operating Resul - GuruFocus.com
Curis Provides Third Quarter 2024 Business Update - GuruFocus.com
Curis: Q3 Earnings Snapshot - Marketscreener.com
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright - Defense World
Curis Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Call Transcript - Insider Monkey
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Fi - GuruFocus.com
Earnings call: Curis Reports Progress in Clinical Studies and Financials - Investing.com India
Curis Inc. Reports Positive Q3 2024 Earnings - TipRanks
Curis reports progress in clinical trials By Investing.com - Investing.com Australia
Curis Inc (CRIS) Quarterly 10-Q Report - Quartzy
Curis Inc (CRIS) Q3 2024 Earnings: Revenue Surpasses Estimates a - GuruFocus.com
Curis reports progress in clinical trials - Investing.com
Curis Reports Improved Q3 Loss, Achieves Strong Clinical Response in Cancer Study | CRIS Stock News - StockTitan
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):